Guardant Health, Inc. (GH) FY2025 10-K Annual Report
Guardant Health, Inc. (GH) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Guardant Health, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Precision oncology company providing liquid biopsy and blood-based tests for cancer detection, treatment selection, and monitoring across all disease stages
- • New emphasis: Expanded Guardant Reveal test for late-stage therapy response monitoring; Shield test granted FDA Breakthrough Device status for multi-cancer detection
- • Strategic shift: Migration of key tests (Guardant360 Liquid, Reveal) to proprietary Smart Platform leveraging multiomic data and AI for enhanced sensitivity and insights
- • Quantitative highlight: Global expansion includes launch of Guardant360 CDx testing at Policlinico Gemelli in Italy (Dec 2025) and reimbursement approval in Japan (July 2023)
- • Noteworthy fact: Shield blood test is first FDA-approved and Medicare-covered primary colorectal cancer screening blood test, now included in NCCN screening guidelines
Management Discussion & Analysis
- • Revenue $982.0M in 2025 vs $739.0M in 2024, up $243M or 32.9% YoY
- • Net loss improved to $416.3M in 2025 from $436.4M in 2024, margin not explicitly stated
- • Best segment: Oncology tests for clinical customers, supported by expanded Medicare coverage and FDA approvals
- • Worst segment: Not explicitly stated; overall net losses indicate ongoing high operating expenses
- • Cash & equivalents $1.3B as of Dec 31, 2025; capital allocation details on buybacks/dividends not disclosed
- • Increased R&D spending on new product innovation and large clinical studies (e.g., Shield post-approval SOLAR study)
- • Management outlook highlights focus on international expansion, payer coverage improvements, and reimbursement risks
Risk Factors
- • Medicare reimbursement 10%+ of revenue in 2025, 2024, 2023; risk from CMS regulation changes hindering direct billing
- • Geopolitical and economic instability, including wars, terrorism, pandemics, may disrupt business and affect operating results
- • Limited laboratory capacity and unautomated processes constrain scaling; facility expansion and equipment procurement delays possible
- • Competitor Roche-owned Foundation Medicine, Exact Sciences, and others increasing M&A and development efforts in liquid biopsy and genomic profiling
- • Revenue concentration: Top 5 biopharmaceutical customers contributed 11% of total revenue in 2025, risking material financial impact if lost
Guardant Health, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$982M
▲ +32.9% YoY
Net Income
-$416M
▲ +4.6% YoY
Operating Margin
-44.5%
▲ +1550bp YoY
Net Margin
-42.4%
▲ +1666bp YoY
ROE
419.2%
▲ +10670bp YoY
Total Assets
$2.0B
▲ +35.5% YoY
EPS (Diluted)
$-3.32
▲ +6.7% YoY
Operating Cash Flow
-$185M
▲ +23.0% YoY
Source: XBRL data from Guardant Health, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Guardant Health, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.